Indraprastha Medical Corporation Limited (INDRAMEDCO) AI Stock Analysis

Indraprastha Medical Corporation Limited

(NSE:INDRAMEDCO)

Select Model

Rating:71Outperform

Price Target:INR 337.00▲(8.57% Upside)

Action:reiterated

Date:08/17/26

The score is primarily supported by strong financial performance, especially revenue growth, margin expansion, low leverage, and positive cash generation. This is tempered by weak technical momentum, while valuation remains acceptable but not especially compelling. Earnings call and corporate event factors are excluded due to missing data.

Positive Factors

Revenue and Profitability RecoveryThe company has expanded revenue consistently while materially improving profitability, showing a healthier operating model than in 2021. This recovery can strengthen internal funding capacity, support reinvestment in clinical services, and provide a more durable earnings base over the next several quarters.

Negative Factors

Slowing Revenue GrowthAlthough revenue continues to increase, the slowdown in 2026 indicates that the recent pace of expansion may be moderating. If this persists, it could limit operating leverage, reduce the speed of earnings compounding, and place greater importance on case mix, pricing, and efficiency improvements.

Indraprastha Medical Corporation Limited (INDRAMEDCO) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 30.86B
Dividend Yield: 1.31%
Average Volume (3M): 18.55K
Price to Earnings (P/E): 14.9
Beta (1Y): 1.71
Revenue Growth: 10.92%
EPS Growth: 12.12%
Country: India
Employees: 3,000
Sector: General
Sector Strength: 55
Industry: Medical - Care Facilities

Indraprastha Medical Corporation Limited Business Overview & Revenue Model

Company Description

Indraprastha Medical Corporation Limited (IMCL) is a prominent Indian healthcare provider, delivering a broad spectrum of hospital services across the nation. The company offers comprehensive medical and surgical solutions across an extensive range o...

How the Company Makes Money

INDRAMEDCO generates revenue primarily by delivering hospital services to patients at its facility. Key revenue streams typically include: (1) Inpatient services (room/bed charges, nursing and care services, intensive care, in-hospital procedures, an...

Indraprastha Medical Corporation Limited Financial Statement Overview

Summary

Strong overall financial profile, led by sustained revenue growth, expanding margins, conservative leverage, and consistently positive free cash flow.

Income Statement

88Very Positive

Balance Sheet

91Very Positive

Cash Flow

84Very Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	15.24B	14.83B	13.56B	12.45B	10.99B	8.88B
Gross Profit	5.16B	5.06B	3.50B	3.13B	6.25B	4.79B
EBITDA	2.95B	2.96B	2.44B	2.07B	1.61B	1.17B
Net Income	1.88B	1.84B	1.61B	1.24B	861.50M	586.20M
Balance Sheet
Total Assets	0	9.91B	8.52B	7.23B	5.55B	4.62B
Cash, Cash Equivalents and Short-Term Investments	2.63B	2.63B	3.19B	2.24B	1.36B	660.10M
Total Debt	0	368.60M	327.60M	339.50M	24.80M	53.10M
Total Liabilities	-7.40B	2.51B	2.55B	2.45B	1.76B	1.36B
Stockholders Equity	7.40B	7.40B	5.97B	4.78B	3.79B	3.25B
Cash Flow
Free Cash Flow	808.10M	1.30B	1.20B	1.31B	998.90M	418.10M
Operating Cash Flow	935.10M	1.89B	1.57B	2.00B	1.44B	712.90M
Investing Cash Flow	-1.47B	-2.02B	-1.11B	-1.58B	-1.08B	-511.00M
Financing Cash Flow	-56.60M	-434.60M	-458.80M	-323.80M	-260.40M	-33.70M

Indraprastha Medical Corporation Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price310.40

Price Trends

50DMA343.78Negative

100DMA358.52Negative

200DMA375.99Negative

Market Momentum

MACD-11.13Negative

RSI34.52Neutral

STOCH62.39Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDRAMEDCO, the sentiment is Negative. The current price of 310.40 is below the 20-day moving average (MA) of 319.93, below the 50-day MA of 343.78, and below the 200-day MA of 375.99, indicating a bearish trend. The MACD of -11.13 indicates Negative momentum. The RSI at 34.52 is Neutral, neither overbought nor oversold. The STOCH value of 62.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:INDRAMEDCO.

Indraprastha Medical Corporation Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:INDRAMEDCO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:MEDANTA	79Outperform	INR 341.22B	61.37	―	0.08%	21.27%	4.09%
IN:ARTEMISMED	73Outperform	INR 46.26B	38.38	―	0.15%	14.96%	20.76%
IN:INDRAMEDCO	71Outperform	INR 27.97B	14.90	―	1.31%	10.92%	12.12%
IN:APOLLOHOSP	62Neutral	INR 1.21T	58.13	―	0.24%	17.20%	32.79%
IN:FORTIS	60Neutral	INR 581.17B	55.34	―	0.13%	17.50%	20.65%
IN:MAXHEALTH	55Neutral	INR 837.05B	57.45	―	0.23%	15.17%	1.63%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

IN:INDRAMEDCO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:INDRAMEDCO	Indraprastha Medical Corporation Limited	310.40	-287.50	-48.08%
IN:APOLLOHOSP	Apollo Hospitals Enterprise Limited	8420.00	626.19	8.03%
IN:ARTEMISMED	Artemis Medicare Services Ltd.	283.65	38.86	15.88%
IN:FORTIS	Fortis Healthcare Ltd.	760.00	-257.52	-25.31%
IN:MAXHEALTH	Max Healthcare Institute Ltd	883.10	-252.38	-22.23%
IN:MEDANTA	Global Health Limited	1298.70	50.24	4.02%

Indraprastha Medical Corporation Limited Corporate Events

Indraprastha Medical Corporation Files SEBI Compliance Certificate for September Quarter

Oct 14, 2026

Indraprastha Medical Corporation Limited has submitted a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30 September 2026. The certificate, issued by registrar and sha...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026

Indraprastha Medical Corporation Limited AI Stock Analysis